Is HARVARD BIOSCIENCE INC (HBIO) Halal?

NASDAQ Healthcare United States $22M
✗ NOT HALAL
Confidence: 90/100
HARVARD BIOSCIENCE INC (HBIO) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 180.9% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. HARVARD BIOSCIENCE INC operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 180.9%
/ 30%
16.7%
/ 30%
60.4%
/ 30%
2.38%
/ 5%
✗ NOT HALAL
DJIM 180.9%
/ 33%
16.7%
/ 33%
60.4%
/ 33%
2.38%
/ 5%
✗ NOT HALAL
MSCI 35.1%
/ 33%
3.2%
/ 33%
11.7%
/ 33%
2.38%
/ 5%
✗ NOT HALAL
S&P 180.9%
/ 33%
16.7%
/ 33%
60.4%
/ 33%
2.38%
/ 5%
✗ NOT HALAL
FTSE 35.1%
/ 33%
3.2%
/ 33%
11.7%
/ 50%
2.38%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-1.28
P/B Ratio
1.6
EV/EBITDA
7.7
EV: $57M
Revenue
$94M
Growth: -3.3%
Beta
1.4
High volatility
Current Ratio
2.2

Profitability

Gross Margin 57.7%
Operating Margin 14.0%
Net Margin -65.5%
Return on Equity (ROE) -147.1%
Return on Assets (ROA) 0.9%

Cash Flow & Balance Sheet

Operating Cash Flow$1M
Free Cash Flow-$2M
Total Debt$44M
Debt-to-Equity322.4
Current Ratio2.2
Total Assets$127M

Price & Trading

Last Close$5.07
50-Day MA$5.47
200-Day MA$5.40
Avg Volume48K
Beta1.4
52-Week Range
$2.80
$9.50

About HARVARD BIOSCIENCE INC (HBIO)

CEO
Mr. John Duke
Employees
316
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NASDAQ
Market Cap
$22M
Currency
USD

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is HARVARD BIOSCIENCE INC (HBIO) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), HARVARD BIOSCIENCE INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is HARVARD BIOSCIENCE INC's debt ratio?

HARVARD BIOSCIENCE INC's debt ratio is 180.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 35.1%.

What are HARVARD BIOSCIENCE INC's key financial metrics?

HARVARD BIOSCIENCE INC has a market capitalization of $22M, and revenue of $94M. The company maintains a gross margin of 57.7% and a net margin of -65.5%. Return on equity stands at -147.1%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.